{"protocolSection": {"identificationModule": {"nctId": "NCT01691521", "orgStudyIdInfo": {"id": "115588"}, "organization": {"fullName": "GlaxoSmithKline", "class": "INDUSTRY"}, "briefTitle": "Efficacy and Safety Study of Mepolizumab Adjunctive Therapy in Subjects With Severe Uncontrolled Refractory Asthma", "officialTitle": "MEA115588 A Randomised, Double-blind, Double-dummy, Placebo-controlled, Parallel-group, Multi-centre Study of the Efficacy and Safety of Mepolizumab Adjunctive Therapy in Subjects With Severe Uncontrolled Refractory Asthma"}, "statusModule": {"statusVerifiedDate": "2018-08", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2012-10-08"}, "primaryCompletionDateStruct": {"date": "2014-01-01", "type": "ACTUAL"}, "completionDateStruct": {"date": "2014-01-18", "type": "ACTUAL"}, "studyFirstSubmitDate": "2012-09-20", "studyFirstSubmitQcDate": "2012-09-20", "studyFirstPostDateStruct": {"date": "2012-09-24", "type": "ESTIMATED"}, "resultsFirstSubmitDate": "2015-11-05", "resultsFirstSubmitQcDate": "2015-12-17", "resultsFirstPostDateStruct": {"date": "2016-01-26", "type": "ESTIMATED"}, "dispFirstSubmitDate": "2015-04-22", "dispFirstSubmitQcDate": "2015-04-22", "dispFirstPostDateStruct": {"date": "2015-05-08", "type": "ESTIMATED"}, "lastUpdateSubmitDate": "2018-08-02", "lastUpdatePostDateStruct": {"date": "2018-08-06", "type": "ACTUAL"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "GlaxoSmithKline", "class": "INDUSTRY"}}, "oversightModule": {"oversightHasDmc": true}, "descriptionModule": {"briefSummary": "This study will evaluate two dose regimens of mepolizumab \\[75mg intravenous (i.v.) or 100mg subcutaneous (SC) every 4 weeks\\] compared with placebo over a 32 week treatment period in subjects with severe refractory asthma with elevated blood eosinophils. Efficacy will be measured by a reduction in the frequency of asthma exacerbations. Additional efficacy assessments will include measurements of lung function, symptom scores, and quality of life. Safety will be assessed by clinical laboratory samples, ECGs, immunogenicity and adverse events.\n\nThis study is intended to replicate the Phase IIb/III study MEA112997. Subjects in MEA115588, who meet all eligibility criteria at screening visit, will enter the run-in period. Those subjects that are not able/eligible to be randomised at the end of the 6 week run-in period will be deemed run-in failures. Subjects will remain on their current maintenance therapy throughout the run-in, double-blind treatment administration and follow-up periods. Subjects who meet the randomisation eligibility criteria will be randomised in a 1:1:1 ratio to receive one of the following treatments every 4 weeks for a total of 8 doses: Mepolizumab 75 miligram (mg) i.v. and placebo SC, or Mepolizumab 100 mg SC and placebo i.v. or Placebo i.v. and placebo SC.\n\nSubjects that receive all 8 doses of double-blind treatment, and meet the eligibility criteria for the Open-Label Extension (OLE) Study, will be offered the opportunity to participate in the OLE trial."}, "conditionsModule": {"conditions": ["Asthma"], "keywords": ["safety", "SB-240563", "efficacy", "placebo", "eosinophils", "mepolizumab", "Severe refractory asthma"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE3"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "PARALLEL", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "DOUBLE", "whoMasked": ["PARTICIPANT", "INVESTIGATOR"]}}, "enrollmentInfo": {"count": 580, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "Mepolizumab IV", "type": "EXPERIMENTAL", "description": "Mepolizumab 75 mg will be administered intravenously approximately every 4 weeks with the last dose at week 32. Subjects in the Mepolizumab IV arm will receive mepolizumab 75 mg intravenously and placebo SC once every 4 weeks with the last dose at Week 28 (total of 8 doses)", "interventionNames": ["Drug: Mepolizumab IV", "Drug: SC Placebo"]}, {"label": "Mepolizumab SC", "type": "EXPERIMENTAL", "description": "Subjects in the Mepolizumab SC arm will receive mepolizumab 100 mg SC and placebo IV once every 4 weeks with the last dose at Week 28 (total of 8 doses)", "interventionNames": ["Drug: Mepolizumab SC", "Drug: IV Placebo"]}, {"label": "Placebo", "type": "PLACEBO_COMPARATOR", "description": "Subjects in the Placebo arm will receive matching placebo SC and placebo IV once every 4 weeks with the last dose at Week 28 (total of 8 doses)", "interventionNames": ["Drug: IV Placebo", "Drug: SC Placebo"]}], "interventions": [{"type": "DRUG", "name": "Mepolizumab IV", "description": "Mepolizumab 75 mg IV will be administered every 4 weeks with the last dose at Week 28", "armGroupLabels": ["Mepolizumab IV"]}, {"type": "DRUG", "name": "Mepolizumab SC", "description": "Mepolizumab 100 mg SC will be administered every 4 weeks with the last dose at Week 28", "armGroupLabels": ["Mepolizumab SC"]}, {"type": "DRUG", "name": "IV Placebo", "description": "Normal saline (placebo) will be administered IV every 4 weeks with the last dose at Week 28", "armGroupLabels": ["Mepolizumab SC", "Placebo"]}, {"type": "DRUG", "name": "SC Placebo", "description": "Normal saline (placebo) will be administered SC every 4 weeks with the last dose at Week 28", "armGroupLabels": ["Mepolizumab IV", "Placebo"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Number of Clinically Significant Exacerbations of Asthma Per Year", "description": "Clinically significant exacerbations of asthma are defined as worsening of asthma which required use of systemic corticosteroids (IV or oral steroid like prednisone, for at least 3 days or a single intramuscular (IM) corticosteroid (CS) dose is required. For maintenance of systemic corticosteroids, at least double the existing maintenance dose for at least 3 days was required) and/or hospitalization and/or emergency department (ED) visits. The frequency of clinically significant exacerbations of asthma over the 32-week treatment period is expressed as the number of exacerbations per year. Analysis of the number of exacerbations performed using a negative binomial model with covariates of treatment group, baseline maintenance OCS therapy (OCS vs. no OCS), region, exacerbations in the year prior to the study (as an ordinal variable) and baseline % predicted FEV1, and with logarithm of time on treatment as an offset variable.", "timeFrame": "From randomization (Week 0) to Week 32 or if Early Withdrawal (EW) 4 weeks post last dose"}], "secondaryOutcomes": [{"measure": "Number of Clinically Significant Exacerbations Requiring Hospitalization (Including Intubation and Admittance to an Intensive Care Unit [ICU]) or ED Visits Per Year", "description": "Clinically significant exacerbations of asthma are defined as worsening of asthma which required use of systemic corticosteroids (IV or oral steroid like prednisone, for at least 3 days or a single intramuscular (IM) corticosteroid (CS) dose is required. For maintenance of systemic corticosteroids, at least double the existing maintenance dose for at least 3 days was required) and/or hospitalization and/or emergency department (ED) visits. The frequency of clinically significant exacerbations of asthma over the 32-week treatment period is expressed as the number of exacerbations per year. Analysis of the number of exacerbations performed using a negative binomial model with covariates of treatment group, baseline maintenance OCS therapy (OCS vs. no OCS), region, exacerbations in the year prior to the study (as an ordinal variable) and baseline % predicted FEV1, and with logarithm of time on treatment as an offset variable.", "timeFrame": "From randomization (Week 0) to Week 32 or if Early Withdrawal (EW) 4 weeks post last dose"}, {"measure": "Number of Clinically Significant Exacerbations Requiring Hospitalization (Including Intubation and Admittance to an ICU) Per Year", "description": "Clinically significant exacerbations of asthma is defined as worsening of asthma which required use of systemic corticosteroids (IV or oral steroid like prednisone, for at least 3 days or a single intramuscular (IM) corticosteroid (CS) dose is required. For maintenance of systemic corticosteroids, at least double the existing maintenance dose for at least 3 days was required) and/or hospitalization. The frequency of clinically significant exacerbations of asthma over the 32-week treatment period is expressed as the number of exacerbations per year. Analysis of the number of exacerbations performed using a negative binomial model with covariates of treatment group, baseline maintenance OCS therapy (OCS vs. no OCS), region, exacerbations in the year prior to the study (as an ordinal variable) and baseline % predicted FEV1, and with logarithm of time on treatment as an offset variable.", "timeFrame": "From randomization (Week 0) to Week 32 or if Early Withdrawal (EW) 4 weeks post last dose"}, {"measure": "Mean Change From Baseline in Clinic Pre-bronchodilator Forced Expiratory Volume in 1 Second (FEV1) at Week 32", "description": "FEV1 is defined as the volume of air expelled from the lungs in 1 second. Pre-bronchodilator FEV1 measurements were taken by spirometry. The change from Baseline is defined as the difference between the value of the endpoint at the time point of interest and the baseline value. Analysis performed using mixed model repeated measures with covariates of baseline, region, baseline maintenance OCS therapy (OCS vs. no OCS), exacerbations in the year prior to the study (as an ordinal variable), treatment and visit, plus interaction terms for visit by baseline and visit by treatment group.", "timeFrame": "Baseline, Week 32"}, {"measure": "Mean Change From Baseline in the St. George's Respiratory Questionnaire Total Score at Week 32", "description": "The St. George's Respiratory Questionnaire is an established instrument, comprising 50 questions, evaluating symptoms, activity, and impacts; to measure Quality of Life in participants with diseases of airway obstruction and to elicit the participant's opinion of his/her health. The lowest possible value is zero and the highest possible value is 100. The higher values correspond to greater impairment in quality of life. The questionnaire was administered at Baseline (Visit 2) and at the Exit Visit (approximately 4 weeks after the last dose of study treatment). The change from baseline is defined as the difference between the value of the endpoint at the time point of interest and the baseline value. Analysis performed using analysis of covariance with covariates of baseline, region, baseline maintenance OCS therapy (OCS vs. no OCS), exacerbations in the year prior to the study (as an ordinal variable), baseline % predicted FEV1, and treatment.", "timeFrame": "Baseline, Week 32"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* Able to give written informed consent prior to participation in the study\n* At least 12 years of age at visit 1 and a minimum weight of 45 kilogram (kg)\n* A well-documented requirement for regular treatment with high dose inhaled corticosteroid (ICS) in the 12 months prior to Visit 1 with or without maintenance oral corticosteroids (OCS)\n* Current treatment with an additional controller medication, besides ICS, for at least 3 months or a documented failure in the past 12 months of an additional controller medication for at least 3 successive months\n* Prior documentation of eosinophilic asthma or high likelihood of eosinophilic asthma\n* At Visit 1, a pre-bronchodilator FEV1 \\<80% (for subjects \\>= 18 years of age), a pre-bronchodilator FEV1 \\<90% or FEV1:FVC ratio \\<0.8 (for subjects 12-17 years of age).\n* Previously confirmed history of two or more exacerbations requiring treatment with systemic CS\n* Male or Eligible Female (females of childbearing potential must commit to consistent and correct use of an acceptable method of birth control)\n* French subjects will be included only if either affiliated to or a beneficiary of a social security category.\n\nExclusion Criteria:\n\n* Current smokers or former smokers with a smoking history of \\>=10 pack years\n* Presence of a known pre-existing, clinically important lung condition other than asthma\n* A current malignancy or previous history of malignancy in less than 12 months\n* Known, pre-existing, unstable liver disease cirrhosis and known biliary abnormalities\n* Known, pre-existing severe or clinically significant cardiovascular disease\n* known, pre-existing other concurrent clinically significant medical conditions that are uncontrolled with standard treatment\n* Subjects with any eosinophilic diseases\n* QTc(F) \u2265450msec or QTc(F) \u2265480 msec\n* A history of alcohol/substance abuse\n* Subject with known immunodeficiency\n* Subjects who have received omalizumab within 130 days of Visit 1 or any monoclonal antibody (other than Xolair) to treat inflammatory disease within 5 half-lives of Visit 1\n* Subjects who have received treatment with an investigational drug within the past 30 days or five terminal phase half-lives of the drug whichever is longer\n* Subjects with allergy/intolerance to a monoclonal antibody or biologic.\n* Subjects who are pregnant or breastfeeding\n* Subjects who have known evidence of lack of adherence to controller medications and/or ability to follow physician's recommendations\n* Previously participated in any study with mepolizumab and received investigational product (including placebo)", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "12 Years", "stdAges": ["CHILD", "ADULT", "OLDER_ADULT"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "GSK Clinical Trials", "affiliation": "GlaxoSmithKline", "role": "STUDY_DIRECTOR"}], "locations": [{"facility": "GSK Investigational Site", "city": "Birmingham", "state": "Alabama", "zip": "35294", "country": "United States", "geoPoint": {"lat": 33.52066, "lon": -86.80249}}, {"facility": "GSK Investigational Site", "city": "Newport Beach", "state": "California", "zip": "92663", "country": "United States", "geoPoint": {"lat": 33.61891, "lon": -117.92895}}, {"facility": "GSK Investigational Site", "city": "Riverside", "state": "California", "zip": "92506", "country": "United States", "geoPoint": {"lat": 33.95335, "lon": -117.39616}}, {"facility": "GSK Investigational Site", "city": "Rolling Hills Estates", "state": "California", "zip": "90274", "country": "United States", "geoPoint": {"lat": 33.78779, "lon": -118.35813}}, {"facility": "GSK Investigational Site", "city": "Denver", "state": "Colorado", "zip": "80206", "country": "United States", "geoPoint": {"lat": 39.73915, "lon": -104.9847}}, {"facility": "GSK Investigational Site", "city": "New Haven", "state": "Connecticut", "zip": "06520", "country": "United States", "geoPoint": {"lat": 41.30815, "lon": -72.92816}}, {"facility": "GSK Investigational Site", "city": "Albany", "state": "Georgia", "zip": "31707", "country": "United States", "geoPoint": {"lat": 31.57851, "lon": -84.15574}}, {"facility": "GSK Investigational Site", "city": "Chicago", "state": "Illinois", "zip": "60612", "country": "United States", "geoPoint": {"lat": 41.85003, "lon": -87.65005}}, {"facility": "GSK Investigational Site", "city": "Baltimore", "state": "Maryland", "zip": "21224", "country": "United States", "geoPoint": {"lat": 39.29038, "lon": -76.61219}}, {"facility": "GSK Investigational Site", "city": "Rochester", "state": "Minnesota", "zip": "55905", "country": "United States", "geoPoint": {"lat": 44.02163, "lon": -92.4699}}, {"facility": "GSK Investigational Site", "city": "New York", "state": "New York", "zip": "10029", "country": "United States", "geoPoint": {"lat": 40.71427, "lon": -74.00597}}, {"facility": "GSK Investigational Site", "city": "Rochester", "state": "New York", "zip": "14642", "country": "United States", "geoPoint": {"lat": 43.15478, "lon": -77.61556}}, {"facility": "GSK Investigational Site", "city": "Durham", "state": "North Carolina", "zip": "27705", "country": "United States", "geoPoint": {"lat": 35.99403, "lon": -78.89862}}, {"facility": "GSK Investigational Site", "city": "Winston-Salem", "state": "North Carolina", "zip": "27103", "country": "United States", "geoPoint": {"lat": 36.09986, "lon": -80.24422}}, {"facility": "GSK Investigational Site", "city": "Cincinnati", "state": "Ohio", "zip": "45229", "country": "United States", "geoPoint": {"lat": 39.12713, "lon": -84.51435}}, {"facility": "GSK Investigational Site", "city": "Cincinnati", "state": "Ohio", "zip": "45231", "country": "United States", "geoPoint": {"lat": 39.12713, "lon": -84.51435}}, {"facility": "GSK Investigational Site", "city": "Cleveland", "state": "Ohio", "zip": "44195", "country": "United States", "geoPoint": {"lat": 41.4995, "lon": -81.69541}}, {"facility": "GSK Investigational Site", "city": "Columbus", "state": "Ohio", "zip": "43221", "country": "United States", "geoPoint": {"lat": 39.96118, "lon": -82.99879}}, {"facility": "GSK Investigational Site", "city": "Hershey", "state": "Pennsylvania", "zip": "17033", "country": "United States", "geoPoint": {"lat": 40.28592, "lon": -76.65025}}, {"facility": "GSK Investigational Site", "city": "Nashville", "state": "Tennessee", "zip": "37203", "country": "United States", "geoPoint": {"lat": 36.16589, "lon": -86.78444}}, {"facility": "GSK Investigational Site", "city": "Salt Lake City", "state": "Utah", "zip": "84132-2409", "country": "United States", "geoPoint": {"lat": 40.76078, "lon": -111.89105}}, {"facility": "GSK Investigational Site", "city": "Mar del Plata", "state": "Buenos Aires", "zip": "7600", "country": "Argentina", "geoPoint": {"lat": -38.00228, "lon": -57.55754}}, {"facility": "GSK Investigational Site", "city": "Mar del Plata", "state": "Buenos Aires", "zip": "B7600FZN", "country": "Argentina", "geoPoint": {"lat": -38.00228, "lon": -57.55754}}, {"facility": "GSK Investigational Site", "city": "San Rafael", "state": "Mendoza", "zip": "5600", "country": "Argentina", "geoPoint": {"lat": -34.61772, "lon": -68.33007}}, {"facility": "GSK Investigational Site", "city": "Rosario", "state": "Santa Fe", "zip": "S2000DBS", "country": "Argentina", "geoPoint": {"lat": -32.94682, "lon": -60.63932}}, {"facility": "GSK Investigational Site", "city": "Buenos Aires", "zip": "C1424BSF", "country": "Argentina", "geoPoint": {"lat": -34.61315, "lon": -58.37723}}, {"facility": "GSK Investigational Site", "city": "Ciudad Aut\u00f3noma de Buenos Aires", "zip": "C1426ABP", "country": "Argentina", "geoPoint": {"lat": -34.61315, "lon": -58.37723}}, {"facility": "GSK Investigational Site", "city": "Mendoza", "zip": "5500", "country": "Argentina", "geoPoint": {"lat": -32.89084, "lon": -68.82717}}, {"facility": "GSK Investigational Site", "city": "New Lambton", "state": "New South Wales", "zip": "2305", "country": "Australia", "geoPoint": {"lat": -32.95, "lon": 151.68333}}, {"facility": "GSK Investigational Site", "city": "Bedford Park", "state": "South Australia", "zip": "5042", "country": "Australia", "geoPoint": {"lat": -35.03333, "lon": 138.56667}}, {"facility": "GSK Investigational Site", "city": "Clayton", "state": "Victoria", "zip": "3168", "country": "Australia", "geoPoint": {"lat": -37.91667, "lon": 145.11667}}, {"facility": "GSK Investigational Site", "city": "Nedlands", "state": "Western Australia", "zip": "6009", "country": "Australia", "geoPoint": {"lat": -31.98184, "lon": 115.8073}}, {"facility": "GSK Investigational Site", "city": "Parkville", "zip": "3052", "country": "Australia", "geoPoint": {"lat": -37.78333, "lon": 144.95}}, {"facility": "GSK Investigational Site", "city": "Bruxelles", "zip": "1020", "country": "Belgium", "geoPoint": {"lat": 50.85045, "lon": 4.34878}}, {"facility": "GSK Investigational Site", "city": "Gent", "zip": "9000", "country": "Belgium", "geoPoint": {"lat": 51.05, "lon": 3.71667}}, {"facility": "GSK Investigational Site", "city": "Leuven", "zip": "3000", "country": "Belgium", "geoPoint": {"lat": 50.87959, "lon": 4.70093}}, {"facility": "GSK Investigational Site", "city": "Li\u00e8ge", "zip": "4000", "country": "Belgium", "geoPoint": {"lat": 50.63373, "lon": 5.56749}}, {"facility": "GSK Investigational Site", "city": "Calgary", "state": "Alberta", "zip": "T2N 4Z6", "country": "Canada", "geoPoint": {"lat": 51.05011, "lon": -114.08529}}, {"facility": "GSK Investigational Site", "city": "Edmonton", "state": "Alberta", "zip": "T6G2E1", "country": "Canada", "geoPoint": {"lat": 53.55014, "lon": -113.46871}}, {"facility": "GSK Investigational Site", "city": "Vancouver", "state": "British Columbia", "zip": "V5Z 1M9", "country": "Canada", "geoPoint": {"lat": 49.24966, "lon": -123.11934}}, {"facility": "GSK Investigational Site", "city": "Winnipeg", "state": "Manitoba", "zip": "R2H 2A6", "country": "Canada", "geoPoint": {"lat": 49.8844, "lon": -97.14704}}, {"facility": "GSK Investigational Site", "city": "Burlington", "state": "Ontario", "zip": "L7N 3V2", "country": "Canada", "geoPoint": {"lat": 43.38621, "lon": -79.83713}}, {"facility": "GSK Investigational Site", "city": "Hamilton", "state": "Ontario", "zip": "L8N 3Z5", "country": "Canada", "geoPoint": {"lat": 43.25011, "lon": -79.84963}}, {"facility": "GSK Investigational Site", "city": "Windsor", "state": "Ontario", "zip": "N8X 5A6", "country": "Canada", "geoPoint": {"lat": 42.30008, "lon": -83.01654}}, {"facility": "GSK Investigational Site", "city": "Montreal", "state": "Quebec", "zip": "H2W 1T8", "country": "Canada", "geoPoint": {"lat": 45.50884, "lon": -73.58781}}, {"facility": "GSK Investigational Site", "city": "Montreal", "state": "Quebec", "zip": "H2X 2P4", "country": "Canada", "geoPoint": {"lat": 45.50884, "lon": -73.58781}}, {"facility": "GSK Investigational Site", "city": "Montreal", "state": "Quebec", "zip": "H4J 1C5", "country": "Canada", "geoPoint": {"lat": 45.50884, "lon": -73.58781}}, {"facility": "GSK Investigational Site", "city": "Quebec City", "state": "Quebec", "zip": "G1V 4G5", "country": "Canada", "geoPoint": {"lat": 46.81228, "lon": -71.21454}}, {"facility": "GSK Investigational Site", "city": "St-Charles-Borrom\u00e9e", "state": "Quebec", "zip": "J6E 2B4", "country": "Canada", "geoPoint": {"lat": 46.05007, "lon": -73.46586}}, {"facility": "GSK Investigational Site", "city": "Trois Rivieres", "state": "Quebec", "zip": "G8T 7A1", "country": "Canada", "geoPoint": {"lat": 46.34515, "lon": -72.5477}}, {"facility": "GSK Investigational Site", "city": "Rancagua", "state": "Reg Del Libert Bern Ohiggins", "zip": "2841959", "country": "Chile", "geoPoint": {"lat": -34.17083, "lon": -70.74444}}, {"facility": "GSK Investigational Site", "city": "Santiago", "zip": "8380453", "country": "Chile", "geoPoint": {"lat": -33.45694, "lon": -70.64827}}, {"facility": "GSK Investigational Site", "city": "Talcahuano", "zip": "4270918", "country": "Chile", "geoPoint": {"lat": -36.72494, "lon": -73.11684}}, {"facility": "GSK Investigational Site", "city": "Le Kremlin-Bic\u00eatre Cedex", "zip": "94275", "country": "France", "geoPoint": {"lat": 48.81471, "lon": 2.36073}}, {"facility": "GSK Investigational Site", "city": "Lille cedex", "zip": "59037", "country": "France", "geoPoint": {"lat": 50.63297, "lon": 3.05858}}, {"facility": "GSK Investigational Site", "city": "Lyon cedex 04", "zip": "69317", "country": "France", "geoPoint": {"lat": 45.74848, "lon": 4.84669}}, {"facility": "GSK Investigational Site", "city": "Marseille cedex 20", "zip": "13915", "country": "France", "geoPoint": {"lat": 43.29551, "lon": 5.38958}}, {"facility": "GSK Investigational Site", "city": "Montpellier cedex 5", "zip": "34295", "country": "France", "geoPoint": {"lat": 43.61092, "lon": 3.87723}}, {"facility": "GSK Investigational Site", "city": "Perpignan", "zip": "66000", "country": "France", "geoPoint": {"lat": 42.69764, "lon": 2.89541}}, {"facility": "GSK Investigational Site", "city": "Saint Pierre cedex", "zip": "97448", "country": "France"}, {"facility": "GSK Investigational Site", "city": "Aschaffenburg", "state": "Bayern", "zip": "63739", "country": "Germany", "geoPoint": {"lat": 49.97704, "lon": 9.15214}}, {"facility": "GSK Investigational Site", "city": "Potsdam", "state": "Brandenburg", "zip": "14478", "country": "Germany", "geoPoint": {"lat": 52.39886, "lon": 13.06566}}, {"facility": "GSK Investigational Site", "city": "Ruedersdorf", "state": "Brandenburg", "zip": "15562", "country": "Germany", "geoPoint": {"lat": 51.1, "lon": 11.45}}, {"facility": "GSK Investigational Site", "city": "Frankfurt am Main", "state": "Hessen", "zip": "60596", "country": "Germany", "geoPoint": {"lat": 50.11552, "lon": 8.68417}}, {"facility": "GSK Investigational Site", "city": "Frankfurt", "state": "Hessen", "zip": "60389", "country": "Germany", "geoPoint": {"lat": 50.11552, "lon": 8.68417}}, {"facility": "GSK Investigational Site", "city": "Frankfurt", "state": "Hessen", "zip": "60596", "country": "Germany", "geoPoint": {"lat": 50.11552, "lon": 8.68417}}, {"facility": "GSK Investigational Site", "city": "Gelnhausen", "state": "Hessen", "zip": "63571", "country": "Germany", "geoPoint": {"lat": 50.20164, "lon": 9.18742}}, {"facility": "GSK Investigational Site", "city": "Neu isenburg", "state": "Hessen", "zip": "63263", "country": "Germany", "geoPoint": {"lat": 50.04832, "lon": 8.69406}}, {"facility": "GSK Investigational Site", "city": "Mainz", "state": "Rheinland-Pfalz", "zip": "55131", "country": "Germany", "geoPoint": {"lat": 49.98419, "lon": 8.2791}}, {"facility": "GSK Investigational Site", "city": "Magdeburg", "state": "Sachsen-Anhalt", "zip": "39112", "country": "Germany", "geoPoint": {"lat": 52.12773, "lon": 11.62916}}, {"facility": "GSK Investigational Site", "city": "Berlin", "zip": "10367", "country": "Germany", "geoPoint": {"lat": 52.52437, "lon": 13.41053}}, {"facility": "GSK Investigational Site", "city": "Hamburg", "zip": "22299", "country": "Germany", "geoPoint": {"lat": 53.57532, "lon": 10.01534}}, {"facility": "GSK Investigational Site", "city": "Napoli", "state": "Campania", "zip": "80131", "country": "Italy", "geoPoint": {"lat": 40.85216, "lon": 14.26811}}, {"facility": "GSK Investigational Site", "city": "Parma", "state": "Emilia-Romagna", "zip": "43125", "country": "Italy", "geoPoint": {"lat": 44.79935, "lon": 10.32618}}, {"facility": "GSK Investigational Site", "city": "Genova", "state": "Liguria", "zip": "16132", "country": "Italy", "geoPoint": {"lat": 44.40478, "lon": 8.94438}}, {"facility": "GSK Investigational Site", "city": "Pietra Ligure (SV)", "state": "Liguria", "zip": "17027", "country": "Italy"}, {"facility": "GSK Investigational Site", "city": "Foggia", "state": "Puglia", "zip": "71100", "country": "Italy", "geoPoint": {"lat": 41.45845, "lon": 15.55188}}, {"facility": "GSK Investigational Site", "city": "Pisa", "state": "Toscana", "zip": "56124", "country": "Italy", "geoPoint": {"lat": 43.70853, "lon": 10.4036}}, {"facility": "GSK Investigational Site", "city": "Perugia", "state": "Umbria", "zip": "06156", "country": "Italy", "geoPoint": {"lat": 43.1122, "lon": 12.38878}}, {"facility": "GSK Investigational Site", "city": "Cittadella PD", "state": "Veneto", "zip": "35013", "country": "Italy"}, {"facility": "GSK Investigational Site", "city": "Chiba", "zip": "296-8602", "country": "Japan", "geoPoint": {"lat": 35.6, "lon": 140.11667}}, {"facility": "GSK Investigational Site", "city": "Fukuoka", "zip": "802-0052", "country": "Japan", "geoPoint": {"lat": 33.6, "lon": 130.41667}}, {"facility": "GSK Investigational Site", "city": "Fukuoka", "zip": "811-1394", "country": "Japan", "geoPoint": {"lat": 33.6, "lon": 130.41667}}, {"facility": "GSK Investigational Site", "city": "Fukuoka", "zip": "832-0059", "country": "Japan", "geoPoint": {"lat": 33.6, "lon": 130.41667}}, {"facility": "GSK Investigational Site", "city": "Gunma", "zip": "370-0615", "country": "Japan", "geoPoint": {"lat": 36.52592, "lon": 138.97142}}, {"facility": "GSK Investigational Site", "city": "Hiroshima", "zip": "732-0052", "country": "Japan", "geoPoint": {"lat": 34.4, "lon": 132.45}}, {"facility": "GSK Investigational Site", "city": "Hokkaido", "zip": "062-8618", "country": "Japan", "geoPoint": {"lat": 43.41104, "lon": 142.88878}}, {"facility": "GSK Investigational Site", "city": "Hokkaido", "zip": "070-8644", "country": "Japan", "geoPoint": {"lat": 43.41104, "lon": 142.88878}}, {"facility": "GSK Investigational Site", "city": "Hyogo", "zip": "651-0072", "country": "Japan"}, {"facility": "GSK Investigational Site", "city": "Hyogo", "zip": "672-8064", "country": "Japan"}, {"facility": "GSK Investigational Site", "city": "Ibaraki", "zip": "319-1113", "country": "Japan", "geoPoint": {"lat": 34.81641, "lon": 135.56828}}, {"facility": "GSK Investigational Site", "city": "Kanagawa", "zip": "252-0392", "country": "Japan", "geoPoint": {"lat": 37.58333, "lon": 139.91667}}, {"facility": "GSK Investigational Site", "city": "Kumamoto", "zip": "861-1196", "country": "Japan", "geoPoint": {"lat": 32.80589, "lon": 130.69182}}, {"facility": "GSK Investigational Site", "city": "Mie", "zip": "515-8544", "country": "Japan"}, {"facility": "GSK Investigational Site", "city": "Okinawa", "zip": "901-2132", "country": "Japan", "geoPoint": {"lat": 26.33583, "lon": 127.80139}}, {"facility": "GSK Investigational Site", "city": "Okinawa", "zip": "904-2293", "country": "Japan", "geoPoint": {"lat": 26.33583, "lon": 127.80139}}, {"facility": "GSK Investigational Site", "city": "Osaka", "zip": "560-8552", "country": "Japan", "geoPoint": {"lat": 34.69374, "lon": 135.50218}}, {"facility": "GSK Investigational Site", "city": "Osaka", "zip": "596-8501", "country": "Japan", "geoPoint": {"lat": 34.69374, "lon": 135.50218}}, {"facility": "GSK Investigational Site", "city": "Tokyo", "zip": "102-0083", "country": "Japan", "geoPoint": {"lat": 35.6895, "lon": 139.69171}}, {"facility": "GSK Investigational Site", "city": "Tokyo", "zip": "103-0027", "country": "Japan", "geoPoint": {"lat": 35.6895, "lon": 139.69171}}, {"facility": "GSK Investigational Site", "city": "Tokyo", "zip": "171-0014", "country": "Japan", "geoPoint": {"lat": 35.6895, "lon": 139.69171}}, {"facility": "GSK Investigational Site", "city": "Tokyo", "zip": "187-0024", "country": "Japan", "geoPoint": {"lat": 35.6895, "lon": 139.69171}}, {"facility": "GSK Investigational Site", "city": "Anyang-Si", "zip": "431-070", "country": "Korea, Republic of", "geoPoint": {"lat": 37.3925, "lon": 126.92694}}, {"facility": "GSK Investigational Site", "city": "Bucheon-si,", "zip": "420-767", "country": "Korea, Republic of", "geoPoint": {"lat": 37.49889, "lon": 126.78306}}, {"facility": "GSK Investigational Site", "city": "Cheongju, Chungcheongbuk-do", "zip": "361-711", "country": "Korea, Republic of"}, {"facility": "GSK Investigational Site", "city": "Daegu", "zip": "705-717", "country": "Korea, Republic of", "geoPoint": {"lat": 35.87028, "lon": 128.59111}}, {"facility": "GSK Investigational Site", "city": "Donggu Gwangju", "zip": "501757", "country": "Korea, Republic of"}, {"facility": "GSK Investigational Site", "city": "Incheon", "zip": "405-760", "country": "Korea, Republic of", "geoPoint": {"lat": 37.45646, "lon": 126.70515}}, {"facility": "GSK Investigational Site", "city": "Jeonju-si, Jeollabuk-Do", "zip": "561-712", "country": "Korea, Republic of"}, {"facility": "GSK Investigational Site", "city": "Kangwon-do", "zip": "220-701", "country": "Korea, Republic of"}, {"facility": "GSK Investigational Site", "city": "Seoul", "zip": "120-752", "country": "Korea, Republic of", "geoPoint": {"lat": 37.566, "lon": 126.9784}}, {"facility": "GSK Investigational Site", "city": "Seoul", "country": "Korea, Republic of", "geoPoint": {"lat": 37.566, "lon": 126.9784}}, {"facility": "GSK Investigational Site", "city": "Suwon, Kyonggi-do", "zip": "443-721", "country": "Korea, Republic of", "geoPoint": {"lat": 37.29111, "lon": 127.00889}}, {"facility": "GSK Investigational Site", "city": "Zapopan", "state": "Jalisco", "zip": "45040", "country": "Mexico", "geoPoint": {"lat": 20.72356, "lon": -103.38479}}, {"facility": "GSK Investigational Site", "city": "Zapopan", "state": "Jalisco", "zip": "45200", "country": "Mexico", "geoPoint": {"lat": 20.72356, "lon": -103.38479}}, {"facility": "GSK Investigational Site", "city": "Monterrey", "state": "Nuevo Le\u00f3n", "zip": "64020", "country": "Mexico", "geoPoint": {"lat": 25.67507, "lon": -100.31847}}, {"facility": "GSK Investigational Site", "city": "M\u00e9xico DF", "zip": "14050", "country": "Mexico", "geoPoint": {"lat": 19.42847, "lon": -99.12766}}, {"facility": "GSK Investigational Site", "city": "Chelyabinsk", "zip": "454106", "country": "Russian Federation", "geoPoint": {"lat": 55.15402, "lon": 61.42915}}, {"facility": "GSK Investigational Site", "city": "Moscow", "zip": "123182", "country": "Russian Federation", "geoPoint": {"lat": 55.75222, "lon": 37.61556}}, {"facility": "GSK Investigational Site", "city": "Saint-Petersburg", "zip": "194354", "country": "Russian Federation", "geoPoint": {"lat": 59.93863, "lon": 30.31413}}, {"facility": "GSK Investigational Site", "city": "St. Petersburg", "zip": "194356", "country": "Russian Federation", "geoPoint": {"lat": 59.93863, "lon": 30.31413}}, {"facility": "GSK Investigational Site", "city": "Alicante", "zip": "03004", "country": "Spain", "geoPoint": {"lat": 38.34517, "lon": -0.48149}}, {"facility": "GSK Investigational Site", "city": "Barcelona", "zip": "08036", "country": "Spain", "geoPoint": {"lat": 41.38879, "lon": 2.15899}}, {"facility": "GSK Investigational Site", "city": "Barcelona", "zip": "08041", "country": "Spain", "geoPoint": {"lat": 41.38879, "lon": 2.15899}}, {"facility": "GSK Investigational Site", "city": "Barcelona", "zip": "08208", "country": "Spain", "geoPoint": {"lat": 41.38879, "lon": 2.15899}}, {"facility": "GSK Investigational Site", "city": "Pozuelo De Alarc\u00f3n/Madrid", "zip": "28223", "country": "Spain"}, {"facility": "GSK Investigational Site", "city": "Kharkiv", "zip": "61124", "country": "Ukraine", "geoPoint": {"lat": 49.98081, "lon": 36.25272}}, {"facility": "GSK Investigational Site", "city": "Kiev", "zip": "03680", "country": "Ukraine", "geoPoint": {"lat": 50.45466, "lon": 30.5238}}, {"facility": "GSK Investigational Site", "city": "Mykolayiv", "zip": "54003", "country": "Ukraine", "geoPoint": {"lat": 46.96591, "lon": 31.9974}}, {"facility": "GSK Investigational Site", "city": "Vinnytsia", "zip": "21018", "country": "Ukraine", "geoPoint": {"lat": 49.23278, "lon": 28.48097}}, {"facility": "GSK Investigational Site", "city": "Bradford", "zip": "BD9 6RJ", "country": "United Kingdom", "geoPoint": {"lat": 53.79391, "lon": -1.75206}}, {"facility": "GSK Investigational Site", "city": "Glasgow", "zip": "G11 6NT", "country": "United Kingdom", "geoPoint": {"lat": 55.86515, "lon": -4.25763}}, {"facility": "GSK Investigational Site", "city": "London", "zip": "EC1M 6BQ", "country": "United Kingdom", "geoPoint": {"lat": 51.50853, "lon": -0.12574}}, {"facility": "GSK Investigational Site", "city": "Plymouth", "zip": "PL6 8DH", "country": "United Kingdom", "geoPoint": {"lat": 50.37153, "lon": -4.14305}}, {"facility": "GSK Investigational Site", "city": "Southampton", "zip": "SO16 6YD", "country": "United Kingdom", "geoPoint": {"lat": 50.90395, "lon": -1.40428}}]}, "referencesModule": {"references": [{"pmid": "34158028", "type": "DERIVED", "citation": "Lemiere C, Taille C, Lee JK, Smith SG, Mallett S, Albers FC, Bradford ES, Yancey SW, Liu MC. Impact of baseline clinical asthma characteristics on the response to mepolizumab: a post hoc meta-analysis of two Phase III trials. Respir Res. 2021 Jun 22;22(1):184. doi: 10.1186/s12931-021-01767-z."}, {"pmid": "34098955", "type": "DERIVED", "citation": "Gibson PG, Prazma CM, Chupp GL, Bradford ES, Forshag M, Mallett SA, Yancey SW, Smith SG, Bel EH. Mepolizumab improves clinical outcomes in patients with severe asthma and comorbid conditions. Respir Res. 2021 Jun 7;22(1):171. doi: 10.1186/s12931-021-01746-4."}, {"pmid": "33475231", "type": "DERIVED", "citation": "Best N, Price RG, Pouliquen IJ, Keene ON. Assessing efficacy in important subgroups in confirmatory trials: An example using Bayesian dynamic borrowing. Pharm Stat. 2021 May;20(3):551-562. doi: 10.1002/pst.2093. Epub 2021 Jan 21."}, {"pmid": "32515118", "type": "DERIVED", "citation": "Wardlaw A, Howarth PH, Israel E, Taille C, Quirce S, Mallett S, Bates S, Albers FC, Kwon N. Fungal sensitization and its relationship to mepolizumab response in patients with severe eosinophilic asthma. Clin Exp Allergy. 2020 Jul;50(7):869-872. doi: 10.1111/cea.13680. Epub 2020 Jun 25. No abstract available."}, {"pmid": "32450626", "type": "DERIVED", "citation": "Kim MK, Park HS, Park CS, Min SJ, Albers FC, Yancey SW, Mayer B, Kwon N. Efficacy and safety of mepolizumab in Korean patients with severe eosinophilic asthma from the DREAM and MENSA studies. Korean J Intern Med. 2021 Mar;36(2):362-370. doi: 10.3904/kjim.2019.198. Epub 2020 May 26."}, {"pmid": "31447130", "type": "DERIVED", "citation": "Khurana S, Brusselle GG, Bel EH, FitzGerald JM, Masoli M, Korn S, Kato M, Albers FC, Bradford ES, Gilson MJ, Price RG, Humbert M. Long-term Safety and Clinical Benefit of Mepolizumab in Patients With the Most Severe Eosinophilic Asthma: The COSMEX Study. Clin Ther. 2019 Oct;41(10):2041-2056.e5. doi: 10.1016/j.clinthera.2019.07.007. Epub 2019 Aug 22."}, {"pmid": "31262378", "type": "DERIVED", "citation": "Khurana S, Lyness JM, Mallett S, Nelsen LM, Prazma CM, Albers FC, Forshag M, Llanos JP, Yancey SW, Ortega HG. Association of depressive symptoms with health status and markers of uncontrolled severe asthma. Allergy Asthma Proc. 2019 Jul 1;40(4):230-239. doi: 10.2500/aap.2019.40.4229."}, {"pmid": "31251094", "type": "DERIVED", "citation": "Nelsen LM, Cockle SM, Gunsoy NB, Jones P, Albers FC, Bradford ES, Mullerova H. Impact of exacerbations on St George's Respiratory Questionnaire score in patients with severe asthma: post hoc analyses of two clinical trials and an observational study. J Asthma. 2020 Sep;57(9):1006-1016. doi: 10.1080/02770903.2019.1630640. Epub 2019 Jun 28."}, {"pmid": "31047111", "type": "DERIVED", "citation": "Yancey SW, Bradford ES, Keene ON. Disease burden and efficacy of mepolizumab in patients with severe asthma and blood eosinophil counts of >/=150-300 cells/muL. Respir Med. 2019 May;151:139-141. doi: 10.1016/j.rmed.2019.04.008. Epub 2019 Apr 8."}, {"pmid": "30954640", "type": "DERIVED", "citation": "Ortega HG, Meyer E, Brusselle G, Asano K, Prazma CM, Albers FC, Mallett SA, Yancey SW, Gleich GJ. Update on immunogenicity in severe asthma: Experience with mepolizumab. J Allergy Clin Immunol Pract. 2019 Sep-Oct;7(7):2469-2475.e1. doi: 10.1016/j.jaip.2019.03.042. Epub 2019 Apr 5. No abstract available."}, {"pmid": "29949045", "type": "DERIVED", "citation": "Ortega H, Menzies-Gow A, Llanos JP, Forshag M, Albers F, Gunsoy N, Bradford ES, Yancey SW, Kraft M. Rapid and Consistent Improvements in Morning PEF in Patients with Severe Eosinophilic Asthma Treated with Mepolizumab. Adv Ther. 2018 Jul;35(7):1059-1068. doi: 10.1007/s12325-018-0727-8. Epub 2018 Jun 15."}, {"pmid": "29398640", "type": "DERIVED", "citation": "Ortega H, Yancey SW, Keene ON, Gunsoy NB, Albers FC, Howarth PH. Asthma Exacerbations Associated with Lung Function Decline in Patients with Severe Eosinophilic Asthma. J Allergy Clin Immunol Pract. 2018 May-Jun;6(3):980-986.e1. doi: 10.1016/j.jaip.2017.12.019. Epub 2018 Feb 15."}, {"pmid": "29258789", "type": "DERIVED", "citation": "Gunsoy NB, Cockle SM, Yancey SW, Keene ON, Bradford ES, Albers FC, Pavord ID. Evaluation of Potential Continuation Rules for Mepolizumab Treatment of Severe Eosinophilic Asthma. J Allergy Clin Immunol Pract. 2018 May-Jun;6(3):874-882.e4. doi: 10.1016/j.jaip.2017.11.026. Epub 2017 Dec 16."}, {"pmid": "28687231", "type": "DERIVED", "citation": "Albers FC, Price RG, Smith SG, Yancey SW. Mepolizumab efficacy in patients with severe eosinophilic asthma receiving different controller therapies. J Allergy Clin Immunol. 2017 Nov;140(5):1464-1466.e4. doi: 10.1016/j.jaci.2017.06.010. Epub 2017 Jul 4. No abstract available."}, {"pmid": "27087007", "type": "DERIVED", "citation": "Magnan A, Bourdin A, Prazma CM, Albers FC, Price RG, Yancey SW, Ortega H. Treatment response with mepolizumab in severe eosinophilic asthma patients with previous omalizumab treatment. Allergy. 2016 Sep;71(9):1335-44. doi: 10.1111/all.12914. Epub 2016 May 24."}, {"pmid": "25199059", "type": "DERIVED", "citation": "Ortega HG, Liu MC, Pavord ID, Brusselle GG, FitzGerald JM, Chetta A, Humbert M, Katz LE, Keene ON, Yancey SW, Chanez P; MENSA Investigators. Mepolizumab treatment in patients with severe eosinophilic asthma. N Engl J Med. 2014 Sep 25;371(13):1198-207. doi: 10.1056/NEJMoa1403290. Epub 2014 Sep 8. Erratum In: N Engl J Med. 2015 Apr 30;372(18):1777."}], "seeAlsoLinks": [{"label": "Researchers can use this site to request access to anonymised patient level data and/or supporting documents from clinical studies to conduct further research.", "url": "https://www.clinicalstudydatarequest.com"}], "availIpds": [{"id": "115588", "type": "Informed Consent Form", "url": "https://www.clinicalstudydatarequest.com", "comment": "For additional information about this study please refer to the GSK Clinical Study Register"}, {"id": "115588", "type": "Annotated Case Report Form", "url": "https://www.clinicalstudydatarequest.com", "comment": "For additional information about this study please refer to the GSK Clinical Study Register"}, {"id": "115588", "type": "Statistical Analysis Plan", "url": "https://www.clinicalstudydatarequest.com", "comment": "For additional information about this study please refer to the GSK Clinical Study Register"}, {"id": "115588", "type": "Clinical Study Report", "url": "https://www.clinicalstudydatarequest.com", "comment": "For additional information about this study please refer to the GSK Clinical Study Register"}, {"id": "115588", "type": "Individual Participant Data Set", "url": "https://www.clinicalstudydatarequest.com", "comment": "For additional information about this study please refer to the GSK Clinical Study Register"}, {"id": "115588", "type": "Study Protocol", "url": "https://www.clinicalstudydatarequest.com", "comment": "For additional information about this study please refer to the GSK Clinical Study Register"}, {"id": "115588", "type": "Dataset Specification", "url": "https://www.clinicalstudydatarequest.com", "comment": "For additional information about this study please refer to the GSK Clinical Study Register"}]}, "ipdSharingStatementModule": {"ipdSharing": "YES", "description": "Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site."}}, "resultsSection": {"participantFlowModule": {"preAssignmentDetails": "A total of 802 participants (par.) were screened; 82 were Screen failures; 140 were Run-in failures; 580 were randomized, of which 576 received at least 1 dose of study drug.", "recruitmentDetails": "Par. who met the eligibility criteria at screening, entered the Run-in period for a minimum of 1 week and a maximum of 6 weeks. Par. who received all 8 doses and met the eligibility criteria were offered the opportunity to participate in an open label extension (OLE) study. Par. not entering the OLE study completed the Follow-up Visit.", "groups": [{"id": "FG000", "title": "Placebo", "description": "Participants received placebo intravenously (IV) plus placebo subcutaneously (SC) every 4 weeks (for a total of 8 doses), with the last dose at Week 28. The SC dose and the IV dose were administered into separate arms. A topical anaesthetic was permitted at the injection site to minimize discomfort, as needed. Rescue personnel and rescue medications (salbutamol/albuterol) /equipment were available throughout the study."}, {"id": "FG001", "title": "Mepolizumab 75 mg IV", "description": "Participants received mepolizumab 75 milligrams (mg) IV plus placebo SC every 4 weeks (for a total of 8 doses), with the last dose at Week 28. The SC dose and the IV dose were administered into separate arms. A topical anaesthetic was permitted at the injection site to minimize discomfort, as needed. Rescue personnel and rescue medications (salbutamol/albuterol) /equipment were available throughout the study."}, {"id": "FG002", "title": "Mepolizumab 100 mg SC", "description": "Participants received placebo IV plus mepolizumab 100 mg SC every 4 weeks (for a total of 8 doses), with the last dose at Week 28. The SC dose and the IV dose were administered into separate arms. A topical anaesthetic was permitted at the injection site to minimize discomfort, as needed. Rescue personnel and rescue medications (salbutamol/albuterol) /equipment were available throughout the study."}], "periods": [{"title": "Overall Study", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "191"}, {"groupId": "FG001", "numSubjects": "191"}, {"groupId": "FG002", "numSubjects": "194"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "179"}, {"groupId": "FG001", "numSubjects": "175"}, {"groupId": "FG002", "numSubjects": "185"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "12"}, {"groupId": "FG001", "numSubjects": "16"}, {"groupId": "FG002", "numSubjects": "9"}]}], "dropWithdraws": [{"type": "Adverse Event", "reasons": [{"groupId": "FG000", "numSubjects": "4"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "1"}]}, {"type": "Lack of Efficacy", "reasons": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "1"}, {"groupId": "FG002", "numSubjects": "2"}]}, {"type": "Protocol Violation", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "3"}, {"groupId": "FG002", "numSubjects": "0"}]}, {"type": "Lost to Follow-up", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "2"}, {"groupId": "FG002", "numSubjects": "2"}]}, {"type": "Physician Decision", "reasons": [{"groupId": "FG000", "numSubjects": "2"}, {"groupId": "FG001", "numSubjects": "1"}, {"groupId": "FG002", "numSubjects": "0"}]}, {"type": "Withdrawal by Subject", "reasons": [{"groupId": "FG000", "numSubjects": "5"}, {"groupId": "FG001", "numSubjects": "9"}, {"groupId": "FG002", "numSubjects": "4"}]}]}]}, "baselineCharacteristicsModule": {"groups": [{"id": "BG000", "title": "Placebo", "description": "Participants received placebo IV plus placebo SC every 4 weeks (for a total of 8 doses), with the last dose at Week 28. The SC dose and the IV dose were administered into separate arms. A topical anaesthetic was permitted at the injection site to minimize discomfort, as needed. Rescue personnel and rescue medications (salbutamol/albuterol) /equipment were available throughout the study."}, {"id": "BG001", "title": "Mepolizumab 75 mg IV", "description": "Participants received mepolizumab 75 mg IV plus placebo SC every 4 weeks (for a total of 8 doses), with the last dose at Week 28. The SC dose and the IV dose were administered into separate arms. A topical anaesthetic was permitted at the injection site to minimize discomfort, as needed. Rescue personnel and rescue medications (salbutamol/albuterol) /equipment were available throughout the study."}, {"id": "BG002", "title": "Mepolizumab 100 mg SC", "description": "Participants received placebo IV plus mepolizumab 100 mg SC every 4 weeks (for a total of 8 doses), with the last dose at Week 28. The SC dose and the IV dose were administered into separate arms. A topical anaesthetic was permitted at the injection site to minimize discomfort, as needed. Rescue personnel and rescue medications (salbutamol/albuterol) /equipment were available throughout the study."}, {"id": "BG003", "title": "Total", "description": "Total of all reporting groups"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "191"}, {"groupId": "BG001", "value": "191"}, {"groupId": "BG002", "value": "194"}, {"groupId": "BG003", "value": "576"}]}], "measures": [{"title": "Age, Continuous", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "Years", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "49.2", "spread": "14.26"}, {"groupId": "BG001", "value": "50.0", "spread": "14.03"}, {"groupId": "BG002", "value": "51.2", "spread": "14.55"}, {"groupId": "BG003", "value": "50.1", "spread": "14.28"}]}]}]}, {"title": "Sex: Female, Male", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "107"}, {"groupId": "BG001", "value": "106"}, {"groupId": "BG002", "value": "116"}, {"groupId": "BG003", "value": "329"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "84"}, {"groupId": "BG001", "value": "85"}, {"groupId": "BG002", "value": "78"}, {"groupId": "BG003", "value": "247"}]}]}]}, {"title": "Race/Ethnicity, Customized", "paramType": "NUMBER", "unitOfMeasure": "Participants", "classes": [{"title": "African American/African Heritage", "categories": [{"measurements": [{"groupId": "BG000", "value": "3"}, {"groupId": "BG001", "value": "6"}, {"groupId": "BG002", "value": "7"}, {"groupId": "BG003", "value": "16"}]}]}, {"title": "American Indian or Alaskan Native", "categories": [{"measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "1"}, {"groupId": "BG003", "value": "1"}]}]}, {"title": "Asian - Central/South Asian Heritage", "categories": [{"measurements": [{"groupId": "BG000", "value": "1"}, {"groupId": "BG001", "value": "1"}, {"groupId": "BG002", "value": "0"}, {"groupId": "BG003", "value": "2"}]}]}, {"title": "Asian - East Asian Heritage", "categories": [{"measurements": [{"groupId": "BG000", "value": "15"}, {"groupId": "BG001", "value": "15"}, {"groupId": "BG002", "value": "15"}, {"groupId": "BG003", "value": "45"}]}]}, {"title": "Asian - Japanese Heritage", "categories": [{"measurements": [{"groupId": "BG000", "value": "18"}, {"groupId": "BG001", "value": "17"}, {"groupId": "BG002", "value": "17"}, {"groupId": "BG003", "value": "52"}]}]}, {"title": "Asian - South East Asian Heritage", "categories": [{"measurements": [{"groupId": "BG000", "value": "4"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "2"}, {"groupId": "BG003", "value": "6"}]}]}, {"title": "White - Arabic/North African Heritage", "categories": [{"measurements": [{"groupId": "BG000", "value": "4"}, {"groupId": "BG001", "value": "3"}, {"groupId": "BG002", "value": "4"}, {"groupId": "BG003", "value": "11"}]}]}, {"title": "White - White/Caucasian/European Heritage", "categories": [{"measurements": [{"groupId": "BG000", "value": "144"}, {"groupId": "BG001", "value": "148"}, {"groupId": "BG002", "value": "148"}, {"groupId": "BG003", "value": "440"}]}]}, {"title": "Mixed Race", "categories": [{"measurements": [{"groupId": "BG000", "value": "2"}, {"groupId": "BG001", "value": "1"}, {"groupId": "BG002", "value": "0"}, {"groupId": "BG003", "value": "3"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "Number of Clinically Significant Exacerbations of Asthma Per Year", "description": "Clinically significant exacerbations of asthma are defined as worsening of asthma which required use of systemic corticosteroids (IV or oral steroid like prednisone, for at least 3 days or a single intramuscular (IM) corticosteroid (CS) dose is required. For maintenance of systemic corticosteroids, at least double the existing maintenance dose for at least 3 days was required) and/or hospitalization and/or emergency department (ED) visits. The frequency of clinically significant exacerbations of asthma over the 32-week treatment period is expressed as the number of exacerbations per year. Analysis of the number of exacerbations performed using a negative binomial model with covariates of treatment group, baseline maintenance OCS therapy (OCS vs. no OCS), region, exacerbations in the year prior to the study (as an ordinal variable) and baseline % predicted FEV1, and with logarithm of time on treatment as an offset variable.", "populationDescription": "Modified Intent-to-Treat (ITT) Population: all participants who were randomized and who received at least one dose of trial medication. 'Modified' implies that, in cases where there is is a discrepancy between randomized and actual treatment the analysis used the actual treatment received by the participant rather than the randomized treatment.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "Number of exacerbations per year", "timeFrame": "From randomization (Week 0) to Week 32 or if Early Withdrawal (EW) 4 weeks post last dose", "groups": [{"id": "OG000", "title": "Placebo", "description": "Participants received placebo IV plus placebo SC every 4 weeks (for a total of 8 doses), with the last dose at Week 28. The SC dose and the IV dose were administered into separate arms. A topical anaesthetic was permitted at the injection site to minimize discomfort, as needed. Rescue personnel and rescue medications (salbutamol/albuterol) /equipment were available throughout the study."}, {"id": "OG001", "title": "Mepolizumab 75 mg IV", "description": "Participants received mepolizumab 75 mg IV plus placebo SC every 4 weeks (for a total of 8 doses), with the last dose at Week 28. The SC dose and the IV dose were administered into separate arms. A topical anaesthetic was permitted at the injection site to minimize discomfort, as needed. Rescue personnel and rescue medications (salbutamol/albuterol) /equipment were available throughout the study."}, {"id": "OG002", "title": "Mepolizumab 100 mg SC", "description": "Participants received placebo IV plus mepolizumab 100 mg SC every 4 weeks (for a total of 8 doses), with the last dose at Week 28. The SC dose and the IV dose were administered into separate arms. A topical anaesthetic was permitted at the injection site to minimize discomfort, as needed. Rescue personnel and rescue medications (salbutamol/albuterol) /equipment were available throughout the study."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "191"}, {"groupId": "OG001", "value": "191"}, {"groupId": "OG002", "value": "194"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "1.74"}, {"groupId": "OG001", "value": "0.93"}, {"groupId": "OG002", "value": "0.83"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.001", "pValueComment": "Hochberg procedure with a gamma parameter of 1 used for multiplicity adjustment.", "statisticalMethod": "Negative binomial model", "paramType": "Rate Ratio", "paramValue": "0.53", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.40", "ciUpperLimit": "0.72", "estimateComment": "Number of exacerbations per year in the mepolizumab 75mg IV arm divided by the number of exacerbations per year in the placebo arm."}, {"groupIds": ["OG000", "OG002"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.001", "pValueComment": "Hochberg procedure with a gamma parameter of 1 used for multiplicity adjustment.", "statisticalMethod": "Negative binomial model", "paramType": "Rate Ratio", "paramValue": "0.47", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.35", "ciUpperLimit": "0.64", "estimateComment": "Number of exacerbations per year in the mepolizumab 100 mg SC arm divided by the number of exacerbations per year in the placebo arm."}]}, {"type": "SECONDARY", "title": "Number of Clinically Significant Exacerbations Requiring Hospitalization (Including Intubation and Admittance to an Intensive Care Unit [ICU]) or ED Visits Per Year", "description": "Clinically significant exacerbations of asthma are defined as worsening of asthma which required use of systemic corticosteroids (IV or oral steroid like prednisone, for at least 3 days or a single intramuscular (IM) corticosteroid (CS) dose is required. For maintenance of systemic corticosteroids, at least double the existing maintenance dose for at least 3 days was required) and/or hospitalization and/or emergency department (ED) visits. The frequency of clinically significant exacerbations of asthma over the 32-week treatment period is expressed as the number of exacerbations per year. Analysis of the number of exacerbations performed using a negative binomial model with covariates of treatment group, baseline maintenance OCS therapy (OCS vs. no OCS), region, exacerbations in the year prior to the study (as an ordinal variable) and baseline % predicted FEV1, and with logarithm of time on treatment as an offset variable.", "populationDescription": "ITT Population", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "Number of exacerbations per year", "timeFrame": "From randomization (Week 0) to Week 32 or if Early Withdrawal (EW) 4 weeks post last dose", "groups": [{"id": "OG000", "title": "Placebo", "description": "Participants received placebo IV plus placebo SC every 4 weeks (for a total of 8 doses), with the last dose at Week 28. The SC dose and the IV dose were administered into separate arms. A topical anaesthetic was permitted at the injection site to minimize discomfort, as needed. Rescue personnel and rescue medications (salbutamol/albuterol) /equipment were available throughout the study."}, {"id": "OG001", "title": "Mepolizumab 75 mg IV", "description": "Participants received mepolizumab 75 mg IV plus placebo SC every 4 weeks (for a total of 8 doses), with the last dose at Week 28. The SC dose and the IV dose were administered into separate arms. A topical anaesthetic was permitted at the injection site to minimize discomfort, as needed. Rescue personnel and rescue medications (salbutamol/albuterol) /equipment were available throughout the study."}, {"id": "OG002", "title": "Mepolizumab 100 mg SC", "description": "Participants received placebo IV plus mepolizumab 100 mg SC every 4 weeks (for a total of 8 doses), with the last dose at Week 28. The SC dose and the IV dose were administered into separate arms. A topical anaesthetic was permitted at the injection site to minimize discomfort, as needed. Rescue personnel and rescue medications (salbutamol/albuterol) /equipment were available throughout the study"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "191"}, {"groupId": "OG001", "value": "191"}, {"groupId": "OG002", "value": "194"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0.20"}, {"groupId": "OG001", "value": "0.14"}, {"groupId": "OG002", "value": "0.08"}]}]}]}, {"type": "SECONDARY", "title": "Number of Clinically Significant Exacerbations Requiring Hospitalization (Including Intubation and Admittance to an ICU) Per Year", "description": "Clinically significant exacerbations of asthma is defined as worsening of asthma which required use of systemic corticosteroids (IV or oral steroid like prednisone, for at least 3 days or a single intramuscular (IM) corticosteroid (CS) dose is required. For maintenance of systemic corticosteroids, at least double the existing maintenance dose for at least 3 days was required) and/or hospitalization. The frequency of clinically significant exacerbations of asthma over the 32-week treatment period is expressed as the number of exacerbations per year. Analysis of the number of exacerbations performed using a negative binomial model with covariates of treatment group, baseline maintenance OCS therapy (OCS vs. no OCS), region, exacerbations in the year prior to the study (as an ordinal variable) and baseline % predicted FEV1, and with logarithm of time on treatment as an offset variable.", "populationDescription": "ITT Population", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "Number of exacerbations per year", "timeFrame": "From randomization (Week 0) to Week 32 or if Early Withdrawal (EW) 4 weeks post last dose", "groups": [{"id": "OG000", "title": "Placebo", "description": "Participants received placebo IV plus placebo SC every 4 weeks (for a total of 8 doses), with the last dose at Week 28. The SC dose and the IV dose were administered into separate arms. A topical anaesthetic was permitted at the injection site to minimize discomfort, as needed. Rescue personnel and rescue medications (salbutamol/albuterol) /equipment were available throughout the study."}, {"id": "OG001", "title": "Mepolizumab 75 mg IV", "description": "Participants received mepolizumab 75 mg IV plus placebo SC every 4 weeks (for a total of 8 doses), with the last dose at Week 28. The SC dose and the IV dose were administered into separate arms. A topical anaesthetic was permitted at the injection site to minimize discomfort, as needed. Rescue personnel and rescue medications (salbutamol/albuterol) /equipment were available throughout the study."}, {"id": "OG002", "title": "Mepolizumab 100 mg SC", "description": "Participants received placebo IV plus mepolizumab 100 mg SC every 4 weeks (for a total of 8 doses), with the last dose at Week 28. The SC dose and the IV dose were administered into separate arms. A topical anaesthetic was permitted at the injection site to minimize discomfort, as needed. Rescue personnel and rescue medications (salbutamol/albuterol) /equipment were available throughout the study"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "191"}, {"groupId": "OG001", "value": "191"}, {"groupId": "OG002", "value": "194"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0.10"}, {"groupId": "OG001", "value": "0.06"}, {"groupId": "OG002", "value": "0.03"}]}]}]}, {"type": "SECONDARY", "title": "Mean Change From Baseline in Clinic Pre-bronchodilator Forced Expiratory Volume in 1 Second (FEV1) at Week 32", "description": "FEV1 is defined as the volume of air expelled from the lungs in 1 second. Pre-bronchodilator FEV1 measurements were taken by spirometry. The change from Baseline is defined as the difference between the value of the endpoint at the time point of interest and the baseline value. Analysis performed using mixed model repeated measures with covariates of baseline, region, baseline maintenance OCS therapy (OCS vs. no OCS), exacerbations in the year prior to the study (as an ordinal variable), treatment and visit, plus interaction terms for visit by baseline and visit by treatment group.", "populationDescription": "ITT Population. Only participants with a Baseline FEV1 available and at least one post-Baseline FEV1 measurement were analyzed.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "Milliliters (mL)", "timeFrame": "Baseline, Week 32", "groups": [{"id": "OG000", "title": "Placebo", "description": "Participants received placebo IV plus placebo SC every 4 weeks (for a total of 8 doses), with the last dose at Week 28. The SC dose and the IV dose were administered into separate arms. A topical anaesthetic was permitted at the injection site to minimize discomfort, as needed. Rescue personnel and rescue medications (salbutamol/albuterol) /equipment were available throughout the study."}, {"id": "OG001", "title": "Mepolizumab 75 mg IV", "description": "Participants received mepolizumab 75 mg IV plus placebo SC every 4 weeks (for a total of 8 doses), with the last dose at Week 28. The SC dose and the IV dose were administered into separate arms. A topical anaesthetic was permitted at the injection site to minimize discomfort, as needed. Rescue personnel and rescue medications (salbutamol/albuterol) /equipment were available throughout the study."}, {"id": "OG002", "title": "Mepolizumab 100 mg SC", "description": "Participants received placebo IV plus mepolizumab 100 mg SC every 4 weeks (for a total of 8 doses), with the last dose at Week 28. The SC dose and the IV dose were administered into separate arms. A topical anaesthetic was permitted at the injection site to minimize discomfort, as needed. Rescue personnel and rescue medications (salbutamol/albuterol) /equipment were available throughout the study"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "189"}, {"groupId": "OG001", "value": "188"}, {"groupId": "OG002", "value": "192"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "86", "spread": "31.4"}, {"groupId": "OG001", "value": "186", "spread": "31.5"}, {"groupId": "OG002", "value": "183", "spread": "31.1"}]}]}]}, {"type": "SECONDARY", "title": "Mean Change From Baseline in the St. George's Respiratory Questionnaire Total Score at Week 32", "description": "The St. George's Respiratory Questionnaire is an established instrument, comprising 50 questions, evaluating symptoms, activity, and impacts; to measure Quality of Life in participants with diseases of airway obstruction and to elicit the participant's opinion of his/her health. The lowest possible value is zero and the highest possible value is 100. The higher values correspond to greater impairment in quality of life. The questionnaire was administered at Baseline (Visit 2) and at the Exit Visit (approximately 4 weeks after the last dose of study treatment). The change from baseline is defined as the difference between the value of the endpoint at the time point of interest and the baseline value. Analysis performed using analysis of covariance with covariates of baseline, region, baseline maintenance OCS therapy (OCS vs. no OCS), exacerbations in the year prior to the study (as an ordinal variable), baseline % predicted FEV1, and treatment.", "populationDescription": "ITT Population. Note that only participants with a Baseline and Week 32 assessment were included in the analysis.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "Scores on a scale", "timeFrame": "Baseline, Week 32", "groups": [{"id": "OG000", "title": "Placebo", "description": "Participants received placebo IV plus placebo SC every 4 weeks (for a total of 8 doses), with the last dose at Week 28. The SC dose and the IV dose were administered into separate arms. A topical anaesthetic was permitted at the injection site to minimize discomfort, as needed. Rescue personnel and rescue medications (salbutamol/albuterol) /equipment were available throughout the study."}, {"id": "OG001", "title": "Mepolizumab 75 mg IV", "description": "Participants received mepolizumab 75 mg IV plus placebo SC every 4 weeks (for a total of 8 doses), with the last dose at Week 28. The SC dose and the IV dose were administered into separate arms. A topical anaesthetic was permitted at the injection site to minimize discomfort, as needed. Rescue personnel and rescue medications (salbutamol/albuterol) /equipment were available throughout the study."}, {"id": "OG002", "title": "Mepolizumab 100 mg SC", "description": "Participants received placebo IV plus mepolizumab 100 mg SC every 4 weeks (for a total of 8 doses), with the last dose at Week 28. The SC dose and the IV dose were administered into separate arms. A topical anaesthetic was permitted at the injection site to minimize discomfort, as needed. Rescue personnel and rescue medications (salbutamol/albuterol) /equipment were available throughout the study"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "177"}, {"groupId": "OG001", "value": "174"}, {"groupId": "OG002", "value": "184"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-9.0", "spread": "1.16"}, {"groupId": "OG001", "value": "-15.4", "spread": "1.16"}, {"groupId": "OG002", "value": "-16.0", "spread": "1.13"}]}]}]}]}, "adverseEventsModule": {"frequencyThreshold": "3", "timeFrame": "On-treatment serious adverse events (SAEs) and non-serious AEs were defined as events occurring from the first dose of investigational product until 28 days after the last dose of investigational product, up to 32 weeks.", "description": "Serious adverse events (SAEs) and Non-serious AEs were collected in members of Intent-to-Treat (ITT) Population, comprised of all participants who were randomized and who received at least one dose of study medication.", "eventGroups": [{"id": "EG000", "title": "Placebo", "description": "Participants received placebo IV plus placebo SC every 4 weeks (for a total of 8 doses), with the last dose at Week 28. The SC dose and the IV dose were administered into separate arms. A topical anaesthetic was permitted at the injection site to minimize discomfort, as needed. Rescue personnel and rescue medications (salbutamol/albuterol) /equipment were available throughout the study.", "seriousNumAffected": 27, "seriousNumAtRisk": 191, "otherNumAffected": 143, "otherNumAtRisk": 191}, {"id": "EG001", "title": "Mepolizumab 75 mg IV", "description": "Participants received mepolizumab 75 mg IV plus placebo SC every 4 weeks (for a total of 8 doses), with the last dose at Week 28. The SC dose and the IV dose were administered into separate arms. A topical anaesthetic was permitted at the injection site to minimize discomfort, as needed. Rescue personnel and rescue medications (salbutamol/albuterol) /equipment were available throughout the study.", "seriousNumAffected": 14, "seriousNumAtRisk": 191, "otherNumAffected": 142, "otherNumAtRisk": 191}, {"id": "EG002", "title": "Mepolizumab 100 mg SC", "description": "Participants received placebo IV plus mepolizumab 100 mg SC every 4 weeks (for a total of 8 doses), with the last dose at Week 28. The SC dose and the IV dose were administered into separate arms. A topical anaesthetic was permitted at the injection site to minimize discomfort, as needed. Rescue personnel and rescue medications (salbutamol/albuterol) /equipment were available throughout the study", "seriousNumAffected": 16, "seriousNumAtRisk": 194, "otherNumAffected": 132, "otherNumAtRisk": 194}], "seriousEvents": [{"term": "Asthma", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 14, "numAtRisk": 191}, {"groupId": "EG001", "numAffected": 9, "numAtRisk": 191}, {"groupId": "EG002", "numAffected": 5, "numAtRisk": 194}]}, {"term": "Pulmonary fibrosis", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 191}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 191}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 194}]}, {"term": "Bronchitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 191}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 191}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 194}]}, {"term": "Herpes zoster", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 191}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 191}, {"groupId": "EG002", "numAffected": 2, "numAtRisk": 194}]}, {"term": "Clostridium difficile infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 191}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 191}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 194}]}, {"term": "Croup infectious", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 191}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 191}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 194}]}, {"term": "Diverticulitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 191}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 191}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 194}]}, {"term": "Influenza", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 191}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 191}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 194}]}, {"term": "Pneumonia", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 191}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 191}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 194}]}, {"term": "Postoperative wound infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 191}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 191}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 194}]}, {"term": "Urosepsis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 191}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 191}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 194}]}, {"term": "Viral upper respiratory tract infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 191}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 191}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 194}]}, {"term": "Vulval abscess", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 191}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 191}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 194}]}, {"term": "Contusion", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 191}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 191}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 194}]}, {"term": "Fractured coccyx", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 191}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 191}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 194}]}, {"term": "Heat stroke", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 191}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 191}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 194}]}, {"term": "Inflammation of wound", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 191}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 191}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 194}]}, {"term": "Rib fracture", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 191}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 191}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 194}]}, {"term": "Road traffic accident", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 191}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 191}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 194}]}, {"term": "Tendon rupture", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 191}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 191}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 194}]}, {"term": "Nephrolithiasis", "organSystem": "Renal and urinary disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 191}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 191}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 194}]}, {"term": "Calculus ureteric", "organSystem": "Renal and urinary disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 191}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 191}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 194}]}, {"term": "Calculus urethral", "organSystem": "Renal and urinary disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 191}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 191}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 194}]}, {"term": "Nephrogenic diabetes insipidus", "organSystem": "Renal and urinary disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 191}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 191}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 194}]}, {"term": "Renal colic", "organSystem": "Renal and urinary disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 191}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 191}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 194}]}, {"term": "Gastrointestinal motility disorder", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 191}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 191}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 194}]}, {"term": "Large intestine perforation", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 191}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 191}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 194}]}, {"term": "Oesophageal spasm", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 191}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 191}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 194}]}, {"term": "Intervertebral disc protrusion", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 191}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 191}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 194}]}, {"term": "Musculoskeletal chest pain", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 191}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 191}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 194}]}, {"term": "Spinal osteoarthritis", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 191}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 191}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 194}]}, {"term": "Hypersensitivity", "organSystem": "Immune system disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 191}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 191}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 194}]}, {"term": "Epilepsy", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 191}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 191}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 194}]}, {"term": "Sciatica", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 191}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 191}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 194}]}, {"term": "Angioedema", "organSystem": "Skin and subcutaneous tissue disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 191}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 191}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 194}]}, {"term": "Dyshidrotic eczema", "organSystem": "Skin and subcutaneous tissue disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 191}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 191}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 194}]}, {"term": "Atrial flutter", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 191}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 191}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 194}]}, {"term": "Intracranial lipoma", "organSystem": "Congenital, familial and genetic disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 191}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 191}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 194}]}, {"term": "Gallbladder disorder", "organSystem": "Hepatobiliary disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 191}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 191}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 194}]}, {"term": "Major depression", "organSystem": "Psychiatric disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 191}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 191}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 194}]}], "otherEvents": [{"term": "Nasopharyngitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 46, "numAtRisk": 191}, {"groupId": "EG001", "numAffected": 45, "numAtRisk": 191}, {"groupId": "EG002", "numAffected": 33, "numAtRisk": 194}]}, {"term": "Headache", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 33, "numAtRisk": 191}, {"groupId": "EG001", "numAffected": 46, "numAtRisk": 191}, {"groupId": "EG002", "numAffected": 39, "numAtRisk": 194}]}, {"term": "Upper respiratory tract infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 27, "numAtRisk": 191}, {"groupId": "EG001", "numAffected": 22, "numAtRisk": 191}, {"groupId": "EG002", "numAffected": 24, "numAtRisk": 194}]}, {"term": "Sinusitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 18, "numAtRisk": 191}, {"groupId": "EG001", "numAffected": 11, "numAtRisk": 191}, {"groupId": "EG002", "numAffected": 18, "numAtRisk": 194}]}, {"term": "Bronchitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 16, "numAtRisk": 191}, {"groupId": "EG001", "numAffected": 14, "numAtRisk": 191}, {"groupId": "EG002", "numAffected": 9, "numAtRisk": 194}]}, {"term": "Asthma", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 16, "numAtRisk": 191}, {"groupId": "EG001", "numAffected": 11, "numAtRisk": 191}, {"groupId": "EG002", "numAffected": 9, "numAtRisk": 194}]}, {"term": "Oropharyngeal pain", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 15, "numAtRisk": 191}, {"groupId": "EG001", "numAffected": 12, "numAtRisk": 191}, {"groupId": "EG002", "numAffected": 7, "numAtRisk": 194}]}, {"term": "Back pain", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 7, "numAtRisk": 191}, {"groupId": "EG001", "numAffected": 11, "numAtRisk": 191}, {"groupId": "EG002", "numAffected": 14, "numAtRisk": 194}]}, {"term": "Arthralgia", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 9, "numAtRisk": 191}, {"groupId": "EG001", "numAffected": 10, "numAtRisk": 191}, {"groupId": "EG002", "numAffected": 11, "numAtRisk": 194}]}, {"term": "Injection site reaction", "organSystem": "General disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 6, "numAtRisk": 191}, {"groupId": "EG001", "numAffected": 5, "numAtRisk": 191}, {"groupId": "EG002", "numAffected": 17, "numAtRisk": 194}]}, {"term": "Cough", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 9, "numAtRisk": 191}, {"groupId": "EG001", "numAffected": 8, "numAtRisk": 191}, {"groupId": "EG002", "numAffected": 5, "numAtRisk": 194}]}, {"term": "Fatigue", "organSystem": "General disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 9, "numAtRisk": 191}, {"groupId": "EG001", "numAffected": 8, "numAtRisk": 191}, {"groupId": "EG002", "numAffected": 5, "numAtRisk": 194}]}, {"term": "Gastroenteritis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 6, "numAtRisk": 191}, {"groupId": "EG001", "numAffected": 10, "numAtRisk": 191}, {"groupId": "EG002", "numAffected": 5, "numAtRisk": 194}]}, {"term": "Pain in extremity", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 10, "numAtRisk": 191}, {"groupId": "EG001", "numAffected": 3, "numAtRisk": 191}, {"groupId": "EG002", "numAffected": 8, "numAtRisk": 194}]}, {"term": "Diarrhoea", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 11, "numAtRisk": 191}, {"groupId": "EG001", "numAffected": 4, "numAtRisk": 191}, {"groupId": "EG002", "numAffected": 5, "numAtRisk": 194}]}, {"term": "Influenza", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 6, "numAtRisk": 191}, {"groupId": "EG001", "numAffected": 10, "numAtRisk": 191}, {"groupId": "EG002", "numAffected": 3, "numAtRisk": 194}]}, {"term": "Abdominal pain upper", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 4, "numAtRisk": 191}, {"groupId": "EG001", "numAffected": 7, "numAtRisk": 191}, {"groupId": "EG002", "numAffected": 7, "numAtRisk": 194}]}, {"term": "Dizziness", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 8, "numAtRisk": 191}, {"groupId": "EG001", "numAffected": 4, "numAtRisk": 191}, {"groupId": "EG002", "numAffected": 6, "numAtRisk": 194}]}, {"term": "Nausea", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 8, "numAtRisk": 191}, {"groupId": "EG001", "numAffected": 4, "numAtRisk": 191}, {"groupId": "EG002", "numAffected": 5, "numAtRisk": 194}]}, {"term": "Urinary tract infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 191}, {"groupId": "EG001", "numAffected": 5, "numAtRisk": 191}, {"groupId": "EG002", "numAffected": 8, "numAtRisk": 194}]}, {"term": "Pharyngitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 3, "numAtRisk": 191}, {"groupId": "EG001", "numAffected": 5, "numAtRisk": 191}, {"groupId": "EG002", "numAffected": 6, "numAtRisk": 194}]}, {"term": "Eczema", "organSystem": "Skin and subcutaneous tissue disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 191}, {"groupId": "EG001", "numAffected": 2, "numAtRisk": 191}, {"groupId": "EG002", "numAffected": 9, "numAtRisk": 194}]}, {"term": "Hypertension", "organSystem": "Vascular disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 4, "numAtRisk": 191}, {"groupId": "EG001", "numAffected": 6, "numAtRisk": 191}, {"groupId": "EG002", "numAffected": 3, "numAtRisk": 194}]}, {"term": "Nasal congestion", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 191}, {"groupId": "EG001", "numAffected": 5, "numAtRisk": 191}, {"groupId": "EG002", "numAffected": 7, "numAtRisk": 194}]}, {"term": "Gastrooesophageal reflux disease", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 3, "numAtRisk": 191}, {"groupId": "EG001", "numAffected": 2, "numAtRisk": 191}, {"groupId": "EG002", "numAffected": 7, "numAtRisk": 194}]}, {"term": "Migraine", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 6, "numAtRisk": 191}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 191}, {"groupId": "EG002", "numAffected": 5, "numAtRisk": 194}]}, {"term": "Myalgia", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 6, "numAtRisk": 191}, {"groupId": "EG001", "numAffected": 3, "numAtRisk": 191}, {"groupId": "EG002", "numAffected": 3, "numAtRisk": 194}]}, {"term": "Rhinitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 4, "numAtRisk": 191}, {"groupId": "EG001", "numAffected": 7, "numAtRisk": 191}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 194}]}, {"term": "Rhinitis allergic", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 4, "numAtRisk": 191}, {"groupId": "EG001", "numAffected": 6, "numAtRisk": 191}, {"groupId": "EG002", "numAffected": 2, "numAtRisk": 194}]}, {"term": "Hypersensitivity", "organSystem": "Immune system disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 3, "numAtRisk": 191}, {"groupId": "EG001", "numAffected": 6, "numAtRisk": 191}, {"groupId": "EG002", "numAffected": 2, "numAtRisk": 194}]}, {"term": "Toothache", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 3, "numAtRisk": 191}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 191}, {"groupId": "EG002", "numAffected": 6, "numAtRisk": 194}]}]}, "moreInfoModule": {"certainAgreement": {"piSponsorEmployee": false, "restrictionType": "OTHER", "restrictiveAgreement": true, "otherDetails": "GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial."}, "pointOfContact": {"title": "GSK Response Center", "organization": "GlaxoSmithKline", "phone": "866-435-7343"}}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-06-24"}, "conditionBrowseModule": {"meshes": [{"id": "D000001249", "term": "Asthma"}], "ancestors": [{"id": "D000001982", "term": "Bronchial Diseases"}, {"id": "D000012140", "term": "Respiratory Tract Diseases"}, {"id": "D000008173", "term": "Lung Diseases, Obstructive"}, {"id": "D000008171", "term": "Lung Diseases"}, {"id": "D000012130", "term": "Respiratory Hypersensitivity"}, {"id": "D000006969", "term": "Hypersensitivity, Immediate"}, {"id": "D000006967", "term": "Hypersensitivity"}, {"id": "D000007154", "term": "Immune System Diseases"}], "browseLeaves": [{"id": "M4556", "name": "Asthma", "asFound": "Asthma", "relevance": "HIGH"}, {"id": "M5258", "name": "Bronchial Diseases", "relevance": "LOW"}, {"id": "M14977", "name": "Respiratory Tract Diseases", "relevance": "LOW"}, {"id": "M11168", "name": "Lung Diseases", "relevance": "LOW"}, {"id": "M11170", "name": "Lung Diseases, Obstructive", "relevance": "LOW"}, {"id": "M10018", "name": "Hypersensitivity", "relevance": "LOW"}, {"id": "M14967", "name": "Respiratory Hypersensitivity", "relevance": "LOW"}, {"id": "M10020", "name": "Hypersensitivity, Immediate", "relevance": "LOW"}, {"id": "M10200", "name": "Immune System Diseases", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC08", "name": "Respiratory Tract (Lung and Bronchial) Diseases"}, {"abbrev": "BC20", "name": "Immune System Diseases"}, {"abbrev": "All", "name": "All Conditions"}]}}, "hasResults": true}